WYETH-AYERST CONJUGATED ESTROGENS FIGHT TAKES ON CONGRESSIONAL FLAVOR: CAPITOL HILL LETTERS TO FDA QUESTION PENDING APPLICATIONS FOR PREMARIN GENERICS
Executive Summary
Wyeth-Ayerst is enlisting political support in its attempt to prevent FDA from approving generic versions of its topselling conjugated estrogens product Premarin. At least eight senators and members of the House have written the agency in the past month to voice concern about the imminent approval of a generic conjugated estrogen product.